Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Sep 1;24(9):1452-1453.
doi: 10.1093/neuonc/noac103.

ONC201 and ONC206: Metabolically ClipPing the wings of diffuse midline glioma

Benjamin Purow  1
Affiliations
Editorial

ONC201 and ONC206: Metabolically ClipPing the wings of diffuse midline glioma

Benjamin Purow. Neuro Oncol. .
No abstract available

PubMed Disclaimer

Comment on

  • Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas.
    Przystal JM, Cianciolo Cosentino C, Yadavilli S, Zhang J, Laternser S, Bonner ER, Prasad R, Dawood AA, Lobeto N, Chin Chong W, Biery MC, Myers C, Olson JM, Panditharatna E, Kritzer B, Mourabit S, Vitanza NA, Filbin MG, de Iuliis GN, Dun MD, Koschmann C, Cain JE, Grotzer MA, Waszak SM, Mueller S, Nazarian J. Przystal JM, et al. Neuro Oncol. 2022 Sep 1;24(9):1438-1451. doi: 10.1093/neuonc/noac041. Neuro Oncol. 2022. PMID: 35157764 Free PMC article.

References

    1. Schwartzentruber J, Korshunov A, Liu XY, et al. . Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012;482(7384):226–231. - PubMed
    1. Majzner RG, Ramakrishna S, Yeom KW, et al. . GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature. 2022;603(7903):934–941. - PMC - PubMed
    1. Arrillaga-Romany I, Chi AS, Allen JE, et al. . A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget. 2017;8(45):79298–79304. - PMC - PubMed
    1. Arrillaga-Romany I, Odia Y, Prabhu VV, et al. . Biological activity of weekly ONC201 in adult recurrent glioblastoma patients. Neuro Oncol. 2020;22(1):94–102. - PMC - PubMed
    1. Chi AS, Tarapore RS, Hall MD, et al. . Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. J Neurooncol. 2019;145(1):97–105. - PMC - PubMed

LinkOut - more resources